gene therapy

Photo
06.01.2025 • News

GemmaBio Secures $34 Million in Funding

Gemma Biotherapeutics (GemmaBio), a new therapeutics company founded by gene therapy pioneer Jim Wilson, recently announced the completion of a $34 million seed funding round to accelerate its groundbreaking gene therapy initiatives.

Photo
25.08.2023 • News

Rentschler in Collaboration to Improve AAV-Manufacturing for Gene Therapies

German CDMO Rentschler Biopharma is collaborating with the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organization specializing in the advancement of cell and gene therapies, and Oxford-based mass photometry specialist Refeyn, to improve the manufacturing adeno-associated viruses (AAVs).

Photo
26.06.2023 • News

Ultragenyx Opens Gene Therapy Manufacturing Plant

US biopharma Ultragenyx Pharmaceutical has opened a gene therapy manufacturing facility in Bedford, Massachusetts, USA. The company said it is one of the first in the US with complete end-to-end gene therapy capabilities, from R&D through to therapeutic production at scale.

Photo
20.10.2022 • News

Lilly Acquires Hearing Loss Specialist Akouos

Lilly has agreed to acquire Akouos, a precision genetic medicine company that is developing gene therapy treatments for hearing loss. Both companies’ boards have approved the deal, which is expected to close in the fourth quarter and cost Lilly up to $610 million.

Photo
19.10.2021 • News

Germany’s Merck Expands CDMO Footprint

Germany’s Merck has opened its second production facility for viral vectors at Carlsbad, California, a move the company said significantly expands its global CDMO footprint. The new €100 million plant will more than double the company’s existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy.

Photo
26.02.2021 • News

Sirion and Sanofi in Gene Therapy Partnership

Germany’s Sirion Biotech has signed a license and collaboration agreement with major French pharma Sanofi on viral vector-based gene therapy. Financial terms of the agreement were not disclosed. The partners aim to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.

Photo
16.09.2020 • News

AveXis now Novartis Gene Therapies

Pharmaceuticals heavyweight Novartis is changing the name of its previously indirect subsidiary AveXis to Novartis Gene Therapies. The Swiss drugmaker said the change signifies the growing importance of gene therapy to building a leading, focused medicines company with advanced therapy platforms. In future, AveXis and Novartis brands will operate under one corporate umbrella.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.